Get the Stockscreener App
2.07
7.25%
0.14
After Hours:
2.08
0.01
+0.48%
Akebia Therapeutics Inc stock is traded at $2.07, with a volume of 6.45M.
It is up +7.25% in the last 24 hours and up +10.70% over the past month.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
See More
Previous Close:
$1.93
Open:
$1.95
24h Volume:
6.45M
Relative Volume:
2.89
Market Cap:
$451.64M
Revenue:
$194.75M
Net Income/Loss:
$-51.26M
P/E Ratio:
-7.3929
EPS:
-0.28
Net Cash Flow:
$-23.38M
1W Performance:
+18.29%
1M Performance:
+10.70%
6M Performance:
+46.81%
1Y Performance:
+45.77%
1-Day Range:
$1.92
$2.09
1-Week Range:
$1.715
$2.09
52-Week Range:
$0.80
$2.48
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Name
Akebia Therapeutics Inc
Sector
Phone
617-871-2098
Address
245 FIRST STREET, CAMBRIDGE, MA
Compare AKBA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
2.07 | 451.64M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Resumed | BTIG Research | Buy |
| Aug-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-31-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-31-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Downgrade | Mizuho | Buy → Neutral |
| Mar-31-22 | Downgrade | Needham | Buy → Hold |
| Mar-31-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Mar-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-19 | Reiterated | Needham | Buy |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-11-19 | Reiterated | H.C. Wainwright | Buy |
| May-02-19 | Initiated | JP Morgan | Overweight |
| Mar-20-19 | Initiated | Citigroup | Neutral |
| Sep-07-18 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-18 | Reiterated | Needham | Buy |
| Jun-06-18 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-17 | Initiated | Piper Jaffray | Overweight |
| Dec-07-17 | Initiated | BTIG Research | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-10-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-27-17 | Reiterated | Needham | Buy |
| Dec-27-16 | Reiterated | H.C. Wainwright | Buy |
| Dec-20-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-15-16 | Initiated | Aegis Capital | Buy |
| Sep-29-16 | Initiated | Brean Capital | Buy |
| Mar-16-16 | Reiterated | Needham | Buy |
| Jan-21-16 | Initiated | Credit Suisse | Neutral |
View All
Akebia Therapeutics Inc Stock (AKBA) Latest News
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Acquired by Barclays PLC - MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listi - GuruFocus.com
Equities Analysts Issue Forecasts for AKBA FY2024 Earnings - Defense World
What is HC Wainwright's Forecast for AKBA FY2024 Earnings? - MarketBeat
Brokers Set Expectations for AKBA FY2024 Earnings - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Sees Significant Increase in Short Interest - MarketBeat
Analysts Offer Predictions for AKBA FY2029 Earnings - MarketBeat
Brokers Issue Forecasts for AKBA FY2029 Earnings - MarketBeat
Akebia Therapeutics (NASDAQ:AKBA) Earns Buy Rating from HC Wainwright - Defense World
Akebia Therapeutics (NASDAQ:AKBA) Rating Lowered to Sell at StockNews.com - MarketBeat
H.C. Wainwright optimistic on Akebia shares despite risks to commercial opportunity - Investing.com Nigeria
HC Wainwright Reiterates "Buy" Rating for Akebia Therapeutics (NASDAQ:AKBA) - MarketBeat
Akebia announces ‘multiple positive business updates’ - Yahoo Finance
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Sold by Jane Street Group LLC - Defense World
Akebia Therapeutics Announces Multiple Positive Business Updates - citybiz
Vafseo tablets start U.S. shipment, Akebia plans Phase 3 trial - Investing.com
Akebia's Vafseo Launch Secures Coverage for Nearly All U.S. Dialysis Patients, 99% of Doctors Show Interest - StockTitan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com
Akebia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Kilgore News Herald
Akebia Therapeutics (NASDAQ:AKBA) Upgraded at StockNews.com - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Stock Holdings Lifted by Barclays PLC - Defense World
Geode Capital Management LLC Has $6.28 Million Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - Defense World
New Strong Sell Stocks for January 3rd - Yahoo Finance
Akebia Therapeutics Awards Inducement Stock Options to New Employee at $1.90 Per Share - StockTitan
Short Interest in Akebia Therapeutics, Inc. (NASDAQ:AKBA) Expands By 21.7% - Defense World
Akebia Therapeutics (NASDAQ:AKBA) Stock Rating Lowered by StockNews.com - MarketBeat
State Street Corp Purchases 683,287 Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Shares Purchased by State Street Corp - Defense World
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Short Interest Update - MarketBeat
Akebia Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights - GuruFocus.com
Wellington Management Group LLP Takes $534,000 Position in Akebia Therapeutics, Inc. (NASDAQ:AKBA) - MarketBeat
High Growth Tech Stocks To Watch In December 2024 - Simply Wall St
Investors in Akebia Therapeutics (NASDAQ:AKBA) have unfortunately lost 73% over the last five years - Yahoo Finance
CMS Grants TDAPA Reimbursement for Vafseo® (vadadustat) beginning January 1, 2025 - The Eastern Progress Online
Akebia Therapeutics CEO to Present Vafseo Launch Updates at J.P. Morgan Healthcare Conference 2024 - StockTitan
Cyclerion Strikes $560M Milestone Deal with Akebia, Completes Portfolio Monetization Strategy - StockTitan
Akebia Therapeutics (NASDAQ:AKBA) Upgraded by StockNews.com to Hold Rating - MarketBeat
Akebia Therapeutics to Present at the Jefferies London Healthcare Conference - The Eastern Progress Online
Akebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference - Kilgore News Herald
Akebia Therapeutics to Present at Upcoming Investor Conferences - The Eastern Progress Online
New Strong Sell Stocks for December 5th - Yahoo Finance
Akebia Therapeutics (FRA:AX9) EBITDA : €4.0 Mil (TTM As of Sep. 2024) - GuruFocus.com
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - Longview News-Journal
Akebia Begins Major Clinical Trial for FDA-Approved Anemia Drug Vafseo - StockTitan
Akebia Therapeutics Inc Stock (AKBA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):